Discussion
As part of preparations for a Phase 3 clinical trial to test its experimental therapy, masitinib, in people with amyotrophic lateral sclerosis (ALS), AB Science has purchased a unique insurance policy. This type of insurance — called clinical trial funding insurance, or CTFI —…